NCAM1 and non-small cell lung carcinoma: In NSCLC patients with disease recurrence or progression after chemotherapy, patients with a BOR of CR, PR, or SD for at least 6 months (n = 25) after treatment with an αPD‐1 inhibitor had significantly increased frequencies of peripheral CD3‒CD56+ NK cells after αPD‐1, an effect not seen in patients with PD or SD less than 6 months duration (n = 15).70